Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. - Wikidata - awgldk - TriplyDB

Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.

Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.

http://www.wikidata.org/entity/Q33849553

about

CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes CRISPR-Cas9 Genome Editing in Drosophila Genome-edited human stem cell-derived beta cells: a powerful tool for drilling down on type 2 diabetes GWAS biology The Rise of CRISPR/Cas for Genome Editing in Stem Cells The therapeutic potential of genome editing for β-thalassemia Genome-editing Technologies for Gene and Cell Therapy CRISPR/Cas9 and cancer targets: future possibilities and present challenges How specific is CRISPR/Cas9 really?Origins of Programmable Nucleases for Genome Engineering Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling Dissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing tools The application of CRISPR-Cas9 genome editing in Caenorhabditis elegans Designed nucleases for targeted genome editing Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference Reprogramming cells with synthetic proteins Off-target Effects in CRISPR/Cas9-mediated Genome Engineering Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9 Quantifying on- and off-target genome editing Low-Dose Irradiation Enhances Gene Targeting in Human Pluripotent Stem Cells Transcription activator-like effector nuclease (TALEN)-mediated CLYBL targeting enables enhanced transgene expression and one-step generation of dual reporter human induced pluripotent stem cell (iPSC) and neural stem cell (NSC) lines.Organoids as a Model for Colorectal Cancer Biased and Unbiased Methods for the Detection of Off-Target Cleavage by CRISPR/Cas9: An Overview Patterns of CRISPR/Cas9 activity in plants, animals and microbes Targeted genome editing in primate embryos Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System Therapeutic genome editing: prospects and challenges CRISPR-Cas9-based knockout of the prion protein and its effect on the proteome IFI16 restricts HSV-1 replication by accumulating on the hsv-1 genome, repressing HSV-1 gene expression, and directly or indirectly modulating histone modifications An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs.The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.CRISPR/Cas9 Immune System as a Tool for Genome Engineering.Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system.CRISPR/Cas9, a powerful tool to target human herpesviruses.Efficient gene targeting in golden Syrian hamsters by the CRISPR/Cas9 system.A CRISPR view of development.A mouse geneticist's practical guide to CRISPR applications.Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line.

P2860

Q22337358-A4AB48E0-D6E2-4037-960A-2924F16E0011 Q26314632-120D82B8-0118-4A8A-9594-FB72C70C624D Q26742051-5499CF6F-B0D0-4E3B-BA8F-FDE34200F59D Q26765852-1D146945-4C24-47E2-B140-D680E488AB1D Q26766232-150F3457-AFB5-45AA-9BC6-995E5F90B492 Q26769662-193E3886-7F1E-4002-9464-B738A7A5A1FB Q26769907-0160097E-184A-4377-8D63-8D05CE697FE2 Q26777801-8C178452-4765-46EB-9AAF-165144138759 Q26778501-69924FB5-55D0-4032-83BB-C14FCD8A1B1B Q26778992-5E702325-CEE0-4CDB-A084-0545C7A51051 Q26782773-0D11E3DE-4314-4493-955D-8503770EDEF7 Q26785684-2410DD80-1EFA-42BE-A917-2F405F357CCD Q26785937-332A1814-6492-44B3-995D-B5F04CB9A380 Q26787105-62E220DC-06C6-438F-BE77-453CEED47071 Q26852489-06792FE7-9E24-4639-8A62-B267815A25EA Q26853155-7AA0388B-6308-40E8-B5F5-1E6575B3E1EF Q26859390-7DA53720-4BF2-4648-AB3B-A6512C39903B Q27011906-6C772BE7-52EC-493A-B687-A971FE39C056 Q27015049-116D3F4C-36FA-4FC3-BAC5-CD84FE3A75AF Q27301084-2B1349D8-528E-4C42-B171-99C43C597527 Q27318385-DF6F421B-C8C4-43D2-9A56-500FFA4C9653 Q28069513-56FAEC98-B1BB-41D6-A086-392E1BC75CC4 Q28069780-76FF3101-36E0-491D-8047-E93690CCBC38 Q28078150-C7910794-C867-4171-9292-36CB1D120FE0 Q28080423-24A4F493-CD46-450B-B2C8-CEDE11D65888 Q28082668-877E21B7-2C80-444B-AE0C-E4C38260FBC6 Q28087380-C139583C-25DC-4085-A9FE-CF6ADB258A8A Q28542611-81503EC2-ACB0-4591-9F1B-C837DC41DDBB Q28544797-31328B93-1598-46B6-8623-E05D93F6C42E Q30250924-11E45FB6-6FF5-4882-807E-DACDADCDBF26 Q30411331-D1D189F4-DFCB-47AF-9A60-9BA8669054BD Q33628110-1F23253E-B985-46DD-A97A-BAEDE361EEA6 Q33688509-473E7014-E5EB-4901-88B6-B2E7D700583F Q33695238-0E1A7CBF-452C-4E23-84E7-FFF45DA5D309 Q33701667-596BFD4A-7817-4607-B849-01896D1077A4 Q34047704-52AA6DBC-48AE-4B3B-B824-9FD9C6100363 Q34316807-D795F93F-46A1-4B51-9D36-47B3D7A50A0F Q34342877-4DF36F9C-2EE7-480C-A175-4377EF2F53FC Q34441174-A23F0F0C-DE6D-4F12-8212-098AC24B3A92 Q34446440-1142A7DA-1F7F-43B9-AE9F-BE7CB0F72621

P2860

Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.

http://www.wikidata.org/entity/Q33849553

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Low incidence of off-target mu ...... ed by whole-genome sequencing.

@ast

Low incidence of off-target mu ...... ed by whole-genome sequencing.

@en

type

label

Low incidence of off-target mu ...... ed by whole-genome sequencing.

@ast

Low incidence of off-target mu ...... ed by whole-genome sequencing.

@en

prefLabel

Low incidence of off-target mu ...... ed by whole-genome sequencing.

@ast

Low incidence of off-target mu ...... ed by whole-genome sequencing.

@en

P1433

Q33849553-6125C0EC-68A0-44A5-892D-5487A9C62976

P1476

Q33849553-086790F6-35F5-4647-8CE1-261CB02B43D7

P2093

Q33849553-1908D69D-3987-48CA-8A79-6AB5D6BA76EA

Q33849553-3CCB7CE8-0D44-436A-A1D9-AA59E0D6C0EE

Q33849553-4809F539-3173-4C1B-9A20-33EF71300BB9

Q33849553-94489E82-85A2-4114-9B24-5485C55D3D14

Q33849553-A6F2E989-B2C6-4948-9521-8500385C7BEE

Q33849553-F052D25B-84C1-45F1-8C55-0947F75C9D9F

Q33849553-F241607B-B383-4834-9667-E951FE459842

P2860

Q33849553-0A990687-C480-40C3-8D59-402FEC262280

Q33849553-171D0A47-C244-490E-BDC7-E5EA157DEEFC

Q33849553-3495A552-4E26-41B0-B219-A5F8FE2FECA5

Q33849553-3B50C6A3-E829-4B7A-A319-FEB161CB55AC

Q33849553-43E691BA-A72F-45D9-8C7E-180F23B92E0B

Q33849553-4C738628-85BD-428D-838F-2F9576AF1A37

Q33849553-5112A2CF-2DE9-4831-AD9F-5FE41BEA8C3A

Q33849553-51951590-2E2E-4C7B-9FA7-410B4C120181

Q33849553-68397CF1-0AD4-4250-BFD9-95FDE2A5321D

Q33849553-6C6C9F56-4ACC-4F2A-A77A-5DD358FDBB44

P304

Q33849553-663BFFBF-FE2C-4857-AC74-392755322F86

P31

Q33849553-4D84F843-E758-4035-AFC4-11ACCB7171C7

P356

Q33849553-20DBB90A-EBDE-44D7-91FF-664199F21BCD

P407

Q33849553-688ADC90-A30F-4E81-A8DC-16D25825A677

P433

Q33849553-443362A5-C73F-4720-9D53-EF03612BBCEC

P478

Q33849553-4958EC9C-B397-4025-AE0C-F10D92640B17

P50

Q33849553-306FD08E-5DCC-44F3-A5E9-C87ECC3FAD6F

Q33849553-46AE0499-322A-4236-B4CA-F6F955D65D78

Q33849553-6862E9FE-FE24-4C7A-8767-08F87AC532AE

P577

Q33849553-704C5C7A-3FB6-4A93-93AC-F6DC311F1B84

P5875

Q33849553-6859B0E1-1833-4259-87EE-2744213930DD

P698

Q33849553-4874EF6A-A6F0-443A-A487-B93C86F0C318

P921

Q33849553-9D81D57E-BF4A-41C2-84EF-97F72D59699F

P932

Q33849553-0EC464D2-3755-448F-B356-CC8BEDB2F35B

P356

J.STEM.2014.04.020

P1433

P1476

Low incidence of off-target mu ...... ted by whole-genome sequencing

@en

P2093

Adrian Veres

http://www.w3.org/2001/XMLSchema#string

Ashok Ragavendran

http://www.w3.org/2001/XMLSchema#string

Bridget S Gosis

http://www.w3.org/2001/XMLSchema#string

Chad A Cowan

http://www.w3.org/2001/XMLSchema#string

Harrison Brand

http://www.w3.org/2001/XMLSchema#string

Kiran Musunuru

http://www.w3.org/2001/XMLSchema#string

Qiurong Ding

http://www.w3.org/2001/XMLSchema#string

P2860

RNA-guided human genome engineering via Cas9

Multiplex genome engineering using CRISPR/Cas systems

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

RNA-programmed genome editing in human cells

Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease

A TALE nuclease architecture for efficient genome editing

CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering

DNA targeting specificity of RNA-guided Cas9 nucleases

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

P304

27-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.STEM.2014.04.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Michael E. Talkowski

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261629615

http://www.w3.org/2001/XMLSchema#string

P698

24996167

http://www.w3.org/2001/XMLSchema#string

P921

P932

4082799

http://www.w3.org/2001/XMLSchema#string